LCS
PROF

Levin Capital Strategies’s Profound Medical PROF Stock Holding History

Levin Capital Strategies’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$84.9K – 282
2023
Q4 		$84.9K Buy
+10,000
New +$95K 0.01% 232

Other funds holding PROF

GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Levin Capital Strategies's PROF Position: Q1 2024 in Review

Levin Capital Strategies sold out of Profound Medical (PROF) in Q1 2024, closing a stake of 10,000 shares — an estimated $84.9K sold.

Levin Capital Strategies first reported a position in PROF in Q4 2023 and held it in 1 quarter. The position peaked at $84.9K in Q4 2023. 43 funds tracked by Wall St. Rank hold PROF as of Q1 2024.

  • Levin Capital Strategies reported no remaining Profound Medical position as of Q1 2024 after selling out during the quarter.
  • Levin Capital Strategies sold 10,000 Profound Medical shares in Q1 2024, an estimated $84.9K.
  • Levin Capital Strategies first reported a position in Profound Medical in Q4 2023 and held it in 1 quarter.
  • Levin Capital Strategies's Profound Medical position peaked at $84.9K in Q4 2023.
  • 43 funds tracked by Wall St. Rank held Profound Medical as of Q1 2024.

Based on Levin Capital Strategies's 13F filing for Q1 2024, filed 16 May 2024.